Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 103 P22 | DOI: 10.1530/endoabs.103.P22

1University of Manchester, Manchester, United Kingdom; 2Manchester University NHS Foundation Trust, Manchester, United Kingdom


56 patients under the care of the paediatric diabetes team at Wythenshawe Hospital were identified as current Omnipod® 5 insulin pump users for Type 1 Diabetes Mellitus management in April 2024. We investigated if use of this HCL caused an increase in daily insulin requirements or an increase in BMI z-score. Time in range (TIR), total daily dose (TDD) of insulin, BMI Z-score along with total daily carbohydrate intake (CHO) and insulin boluses (TDB) during the first six months of pump therapy were compared against those of their previous insulin regime. Data was collected from the Manchester Foundation Trust’s HIVE EPR system, Dexcom Clarity and Glooko. We found a significant increase in the TDD during the first three months of use with an average increase of 31% in the first month and 24% in the first month. However, after 6 months of therapy there was no significant difference between TDD before and after use. This was correlated with a statistically significant increase in CHO and TDB after 1 month of use, but these increases became insignificant after 3 months for CHO and 6 months for TDB. We found that there was no increase in BMI z-scores after both 3 and 6 months of therapy and furthermore, there was no correlation between increasing TDD and BMI z-score. Although the analysis was limited by incomplete patient records and a small sample size, a statistically significant increase in TIR was observed at 1, 3 and 6 months following transition, with 22 patients achieving a TIR above 60% after 6 months of use. After 6 months average TIR increased from 49.0% to 63.0% (P < 0.0001). The most dramatic increase in TIR was observed in the cohort of patients under 5 years of age who previously used multiple daily injections (n = 4), from an average baseline TIR of 31.75% to 61.5% after 6 months of Omnipod® 5 use. In conclusion, this study has shown a clear improvement in overall glycaemic control in our paediatric patients using Omnipod® 5 and no adverse effects regarding increased insulin requirements or BMI z-score.

Volume 103

51st Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes

Glasgow, UK
08 Oct 2024 - 10 Oct 2024

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.